Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419003
Status:
COMPLETED
Last Update Posted:
2019-07-31
First Post:
2007-01-04
Brief Title:
Research Study for Major Depressive Disorder Investigation of Glutamate Medications
Sponsor:
Baylor College of Medicine
Organization:
Baylor College of Medicine
Study Overview
Official Title:
Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is examining the safety and effectiveness of two medications ketamine and riluzole in treating patients with treatment resistant major depressive disorder This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine
Detailed Description:
This research proposal will investigate a glutamate-modulating agent riluzole in treatment-resistant patients who exhibit an acute sustained response to a single dose of intravenous IV racemic ketamine Fifty ketamine-responders will be randomized to riluzole or placebo in a 4-week randomized double-blind continuation-phase study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5M01RR000071-46 | NIH | None | httpsreporternihgovquickSearch5M01RR000071-46 |